238 related articles for article (PubMed ID: 23852927)
1. [Intravesical therapy with mitomycin through electromotive drug administration].
Verri C; Liberati E; Celestino F; De Carlo F; Torelli F; Di Stasi SM
Urologia; 2013; 80(2):105-11. PubMed ID: 23852927
[TBL] [Abstract][Full Text] [Related]
2. Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
Di Stasi SM; Riedl C
World J Urol; 2009 Jun; 27(3):325-30. PubMed ID: 19234707
[TBL] [Abstract][Full Text] [Related]
3. Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400
[TBL] [Abstract][Full Text] [Related]
4. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
5. Intravesical electro-osmotic administration of mitomycin C.
Di Stasi SM; Verri C; Celestino F; De Carlo F; Pagliarulo V
Urologia; 2016 Oct; 83(Suppl 2):18-23. PubMed ID: 27716887
[TBL] [Abstract][Full Text] [Related]
6. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.
Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi PF
BMC Cancer; 2018 Dec; 18(1):1224. PubMed ID: 30522445
[TBL] [Abstract][Full Text] [Related]
7. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
[TBL] [Abstract][Full Text] [Related]
8. Intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
Di Stasi SM; Liberati E; Dutto L; Verri C
Arch Ital Urol Androl; 2008 Dec; 80(4):157-61. PubMed ID: 19235432
[TBL] [Abstract][Full Text] [Related]
9. Single ablative intravesical electromotive mitomycin C administration for small non-muscle-invasive bladder cancer: a prospective study.
Decaestecker K; Lumen N; Van Camp C; Oosterlinck W
Acta Clin Belg; 2018 Oct; 73(5):324-327. PubMed ID: 29451102
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer.
Melgarejo-Segura MT; Morales-Martínez A; Yáñez-Castillo Y; Arrabal-Polo MÁ; Gómez-Lechuga P; Pareja-Vílchez M; Jiménez-Moleón JJ; Martín MA
Urol Oncol; 2023 Apr; 41(4):166-176. PubMed ID: 36328923
[TBL] [Abstract][Full Text] [Related]
11. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.
Juvet T; Mari A; Lajkosz K; Wallis CJ; Kuk C; Erlich A; Krimus L; Fleshner NE; Kulkarni GS; Zlotta AR
Urol Oncol; 2020 Nov; 38(11):850.e9-850.e15. PubMed ID: 32712139
[TBL] [Abstract][Full Text] [Related]
12. Intravesical Treatment with Electro-Mediated Administration of Mytomicin C as Prophylaxis for Intermediate and High-Risk Nonmuscle-Invasive Bladder Cancer: A Retrospective Multicenter Study.
Carando R; Zazzara M; Cotrufo S; Ludovico GM
Urol Int; 2019; 103(3):285-290. PubMed ID: 31461726
[TBL] [Abstract][Full Text] [Related]
13. [Non-muscle invasive bladder cancer: safety of postoperative EMDA-assisted instillation of mitomycin].
Rehme C; Niedworok C; Rübben H; Vom Dorp F
Urologe A; 2015 Feb; 54(2):235-8. PubMed ID: 25316185
[TBL] [Abstract][Full Text] [Related]
14. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
[TBL] [Abstract][Full Text] [Related]
15. Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy).
Pierconti F; Straccia P; Emilio S; Bassi PF; De Pascalis I; Marques RC; Volavsek M; Larocca LM; Lopez-Beltran A
Pathol Res Pract; 2017 Sep; 213(9):1078-1081. PubMed ID: 28843746
[TBL] [Abstract][Full Text] [Related]
16. [Intravesical Electromotive Drug Administration®(EMDA)with Mitomycin-C for non-muscle invasive bladder cancer].
Di Stasi SM; Dutto L; Verri C
Urologia; 2008; 75(4):214-20. PubMed ID: 21086335
[TBL] [Abstract][Full Text] [Related]
17. BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301).
Hayne D; Stockler M; McCombie SP; Chalasani V; Long A; Martin A; Sengupta S; Davis ID
BMC Cancer; 2015 May; 15():432. PubMed ID: 26014129
[TBL] [Abstract][Full Text] [Related]
18. Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
Melgarejo Segura MT; Morales Martínez A; Yáñez Castillo Y; Arrabal Polo MÁ; Gómez Lechuga P; Pareja Vílchez M; Arrabal Martín M
Urol Oncol; 2023 Feb; 41(2):109.e1-109.e8. PubMed ID: 36379812
[TBL] [Abstract][Full Text] [Related]
19. [EMDA with MMC. Critical review.].
Solsona E
Arch Esp Urol; 2018 May; 71(4):409-416. PubMed ID: 29745930
[TBL] [Abstract][Full Text] [Related]
20. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
Kalsi J; Harland SJ; Feneley MR
Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
